Relationships between changes in bone mineral density or bone turnover markers and vertebral fracture incidence in patients treated with bazedoxifene

Calcified Tissue International

Volumn 91, Issue 4, 2012, Pages 244-249

  Bruyère, Olivier ^a   Detilleux, Johann ^a   Chines, Arkadi ^b   Reginster, Jean Yves ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b PFIZER INC   (United States)

Author keywords

Bazedoxifene; Bone turnover marker; DEXA; Fracture

Indexed keywords

BAZEDOXIFENE; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; PLACEBO; RALOXIFENE;

AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FEMUR NECK FRACTURE; FOLLOW UP; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT OUTCOME; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; LOGISTIC MODELS; MIDDLE AGED; PEPTIDES; PLACEBO EFFECT; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SPINAL FRACTURES; SPINE;

EID: 84866028946     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-012-9629-y     Document Type: Article

References (53)

1. Miller PD (2005) Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Curr Osteoporos Rep 3(3):103-110
2. Bonnick SL, Shulman L (2006) Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med 119(Suppl 1):S25-S31
3. Miller PD (2007) Monitoring osteoporosis therapies. Curr Osteoporos Rep 5(1):38-43 (Pubitemid 46447930)
4. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K et al (1993) Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 341(8837):72-75 (Pubitemid 23028113)
5. Melton LJ 3rd, Atkinson EJ, O'FallonWM, WahnerHW, Riggs BL (1993) Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 8(10):1227-1233 (Pubitemid 23308116)
6. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312(7041):1254-1259 (Pubitemid 26147662)
7. Bruyere O, Varela AR, Adami S, Detilleux J, Rabenda V, Hiligsmann M et al (2009) Loss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal women. Eur J Epidemiol 24(11):707-712
8. Seeman E (2007) Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy? Bone 41(3): 308-317 (Pubitemid 47199158)
9. Bruyere O, Roux C, Badurski J, Isaia G, de Vernejoul MC, Cannata J et al (2007) Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate. Curr Med Res Opin 23(12):3041-3045
10. Bruyere O, Roux C, Detilleux J, Slosman DO, Spector TD, Fardellone P et al (2007) Relationship between bone mineral density changes and fracture risk reduction in patients treatedwith strontium ranelate. J Clin Endocrinol Metab 92(8):3076-3081 (Pubitemid 47236373)
11. Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH (2006) Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 21(11):1785-1790 (Pubitemid 46141234)
12. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ et al (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112(4):281-289 (Pubitemid 34219441)
13. Delmas PD, Li Z, Cooper C (2004) Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res 19(2):330-337 (Pubitemid 38116748)
14. Delmas PD, Seeman E (2004) Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 34(4):599-604 (Pubitemid 38393794)
15. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD (2002) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87(4):1586-1592 (Pubitemid 34615244)
16. Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC et al (1999) Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 42(6):1246-1254 (Pubitemid 29268962)
17. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD (2002) Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17(1):1-10 (Pubitemid 33150990)
18. Wasnich RD, Miller PD (2000) Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85(1):231-236 (Pubitemid 32268819)
19. Rabenda V, Bruyere O, Reginster JY (2011) Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression. Osteoporos Int 22(3):893-901
20. Austin M, Yang YC, Vittinghoff E, Adami S, Boonen S, Bauer DC et al (2012) Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res 27(3):687-693
21. Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, Griesmacher A et al (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22(2):391-420
22. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM et al (2005) Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20(6):962-970 (Pubitemid 40712820)
23. Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ et al (2006) Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 91(4):1370-1375
24. Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D et al (2004) Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34(2):344-351 (Pubitemid 38177616)
25. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18(6):1051-1056 (Pubitemid 37294942)
26. Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C (2001) Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12(11):922-930 (Pubitemid 34001005)
27. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J et al (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19(8):1250-1258 (Pubitemid 41094365)
28. Garnero P (2008) Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring. Mol Diagn Ther 12(3):157-170 (Pubitemid 351754589)
29. Delmas PD, Munoz F, Black DM, Cosman F, Boonen S, Watts NB et al (2009) Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res 24(9):1544-1551
30. Bruyere O, Collette J, Rizzoli R, Decock C, Ortolani S, Cormier C et al (2010) Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years. Osteoporos Int 21(6):1031-1036
31. Chines AA, Komm BS (2009) Bazedoxifene acetate: a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. Drugs Today (Barc) 45(7):507-520
32. Palacios S (2010) Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. Curr Med Res Opin 26(7):1553-1563
33. Christiansen C, Chesnut CH III, Adachi JD, Brown JP, Fernandes CE, Kung AW et al (2010) Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskelet Disord 11:130
34. de Villiers TJ, Chines AA, Palacios S, Lips P, Sawicki AZ, Levine AB et al (2011) Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 22(2):567-576
35. Harvey JA, Holm MK, Ranganath R, Guse PA, Trott EA, Helzner E (2009) The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis. Menopause 16(6):1193-1196
36. Itabashi A, Yoh K, Chines AA, Miki T, Takada M, Sato H et al (2011) Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal Japanese women with osteoporosis. J Bone Miner Res 26(3):519-529
37. Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44(6):1049-1054
38. Pinkerton JV, Archer DF, Utian WH, Menegoci JC, Levine AB, Chines AA et al (2009) Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. Menopause 16(6):1102-1108
39. Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ et al (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and activecontrolled clinical trial. J Bone Miner Res 23(12):1923-1934
40. Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8(9):1137-1148 (Pubitemid 23261108)
41. Li Z, Meredith MP, Hoseyni MS (2001) A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med 20(21):3175-3188 (Pubitemid 33034879)
42. Li Z, Chines AA, Meredith MP (2004) Statistical validation of surrogate endpoints: is bone density a valid surrogate for fracture? J Musculoskelet Neuronal Interact 4(1):64-74 (Pubitemid 38714796)
43. Watts NB, Cooper C, Lindsay R, Eastell R, Manhart MD, Barton IP et al (2004) Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 7(3):255-261 (Pubitemid 39178892)
44. Chapurlat RD, Palermo L, Ramsay P, Cummings SR (2005) Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int 16(7):842-848 (Pubitemid 40933602)
45. Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM et al (2005) Compliance with osteoporosis medications. Arch Intern Med 165(20):2414-2419 (Pubitemid 41640855)
46. Liu G, Peacock M, Eilam O, Dorulla G, Braunstein E, Johnston CC (1997) Effect of osteoarthritis in the lumbar spine and hip on bone mineral density and diagnosis of osteoporosis in elderly men and women. Osteoporos Int 7(6):564-569 (Pubitemid 28009018)
47. Kleerekoper M, Villanueva AR, Stanciu J, Rao DS, Parfitt AM (1985) The role of three-dimensional trabecular microstructure in the pathogenesis of vertebral compression fractures. Calcif Tissue Int 37(6):594-597 (Pubitemid 16197165)
48. Legrand E, Chappard D, Pascaretti C, Duquenne M, Krebs S, Rohmer V et al (2000) Trabecular bone microarchitecture, bone mineral density, and vertebral fractures in male osteoporosis. J Bone Miner Res 15(1):13-19 (Pubitemid 30026927)
49. Boonen S, Haentjens P, Vandenput L, Vanderschueren D (2004) Preventing osteoporotic fractures with antiresorptive therapy: implications of microarchitectural changes. J Intern Med 255(1): 1-12 (Pubitemid 38121916)
50. Borah B, Dufresne TE, Cockman MD, Gross GJ, Sod EW, Myers WR et al (2000) Evaluation of changes in trabecular bone architecture and mechanical properties of minipig vertebrae by three-dimensional magnetic resonance microimaging and finite element modeling. J Bone Miner Res 15(9):1786-1797 (Pubitemid 30666232)
51. Miller PD, Chines AA, Christiansen C, Hoeck HC, Kendler DL, Lewiecki EM et al (2008) Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 23(4):525-535 (Pubitemid 351501893)
52. Hashidate H, Kamimura M, Nakagawa H, Takahara K, Ikegami S, Uchiyama S et al (2011) Early changes in bone specific turnover markers during the healing process after vertebral fracture. Open Orthop J 5:32-36
53. Obrant KJ, Ivaska KK, Gerdhem P, Alatalo SL, Pettersson K, Vaananen HK (2005) Biochemical markers of bone turnover are influenced by recently sustained fracture. Bone 36(5):786-792 (Pubitemid 40616013)